^
HER-2 positive
Gastroesophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Gastroesophageal Cancer
PD1 inhibitor
Sensitive: B - Late Trials
PD-L1 overexpression
Gastroesophageal Cancer
PD-L1 inhibitor
Sensitive: B - Late Trials
HER-2 amplification
Gastroesophageal Cancer
trastuzumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Cancer
pembrolizumab
Sensitive: C1 - Off-label
HER-2 positive
Gastroesophageal Cancer
pembrolizumab + trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Gastroesophageal Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Gastroesophageal Cancer
Immunotherapy
Resistant: C3 – Early Trials
TET1 mutation
Gastroesophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
PD-L1 expression
Gastroesophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 overexpression
Gastroesophageal Cancer
disitamab vedotin
Sensitive: C3 – Early Trials
PD-L1 expression
Gastroesophageal Cancer
tislelizumab
Sensitive: C3 – Early Trials
FGFR2 amplification
Gastroesophageal Cancer
ABSK091
Sensitive: C3 – Early Trials
MET amplification
Gastroesophageal Cancer
crizotinib
Sensitive: C3 – Early Trials
TGFB1 elevation
Gastroesophageal Cancer
M7824
Sensitive: C3 – Early Trials
HER-2 overexpression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
MET amplification
Gastroesophageal Cancer
afatinib
Resistant: C3 – Early Trials
EGFR amplification + ERBB2 amplification
Gastroesophageal Cancer
afatinib
Sensitive: C3 – Early Trials
CFB overexpression
Gastroesophageal Cancer
sunitinib
Sensitive: C3 – Early Trials
VEGFC-H
Gastroesophageal Cancer
sunitinib
Sensitive: C3 – Early Trials
HER-2 positive
Gastroesophageal Cancer
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
POLE mutation
Gastroesophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
POLD1 mutation
Gastroesophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
Gastroesophageal Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 expression
Gastroesophageal Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
HER-2 positive + HER-2 amplification
Gastroesophageal Cancer
trastuzumab
Sensitive: C3 – Early Trials
CTAG1A expression
Gastroesophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 positive + PD-L1 expression
Gastroesophageal Cancer
margetuximab + retifanlimab
Sensitive: C3 – Early Trials
HER-2 mutation
Gastroesophageal Cancer
dasatinib
Sensitive: D – Preclinical
HER-2 mutation
Gastroesophageal Cancer
neratinib
Sensitive: D – Preclinical
HER-2 mutation
Gastroesophageal Cancer
dasatinib + neratinib
Sensitive: D – Preclinical
BCL2 overexpression + MCL1 overexpression
Gastroesophageal Cancer
AT 101
Sensitive: D – Preclinical
ERBB2 G778A + CCNE1 amplification
Gastroesophageal Cancer
AZD1775 + fam-trastuzumab deruxtecan-nxki
Sensitive: D – Preclinical
HER2 underexpression + CCNE1 amplification
Gastroesophageal Cancer
AZD1775 + fam-trastuzumab deruxtecan-nxki
Sensitive: D – Preclinical
HER2 amplification + CCNE1 expression
Gastroesophageal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: D – Preclinical
HER2 overexpression + CCNE1 amplification
Gastroesophageal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: D – Preclinical
MET amplification
Gastroesophageal Cancer
savolitinib + capmatinib
Sensitive: D – Preclinical